0GTN
BioGaia AB Series B
Stock London Stock Exchange – Stock Market Prices, News & Analysis
BioGaia AB develops, manufactures and markets probiotics for human health, including for digestion and oral health.
BioGaia AB Series B
0GTN
BioGaia AB develops, manufactures and markets probiotics for human health, including for digestion and oral health.
Price history of BioGaia AB Series B
Price history of BioGaia AB Series B
Performance & Momentum
Strategic Analysis
BioGaia AB Series B • 2026
BioGaia AB positions itself as a European specialist in probiotics, targeting digestive and oral health through an innovative portfolio centered on the human microbiome. Its business model is built on deep scientific research and the commercialization of clinically validated solutions, giving it a strong niche within the healthcare and biotechnology sectors.
- Recognized expertise in probiotics and microbiome research
- Product portfolio focused on clinically proven applications in digestive and oral health
- Established presence in Europe, enhancing its credibility and market access
- Vulnerability to regulatory changes specific to the biotechnology sector
- Mixed shareholder performance over a one-year horizon, indicating fluctuations that may weigh on short-term attractiveness
Moderate momentum reflects a stable but limited trajectory, with solid long-term performance contrasted by recent volatility. The lack of major news suggests an operational status quo, pointing to a strategic consolidation phase before a potential new upward move.
Similar stocks to BioGaia AB Series B
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
